160 related articles for article (PubMed ID: 33563640)
1. Impact of clinical factors and surgical outcome on long-term survival in high-grade serous ovarian cancer: a multicenter analysis.
Baum J; Braicu EI; Hunsicker O; Vergote I; Concin N; Van Nieuwenhuysen E; Feldheiser A; Achimas-Cadariu P; Darb-Esfahani S; Berger A; Fetica B; Mahner S; Papadia A; Wölber L; Gasparri ML; Vanderstichele A; Benedetti Panici P; Mueller MD; Ruscito I; Woopen H; Sehouli J
Int J Gynecol Cancer; 2021 May; 31(5):713-720. PubMed ID: 33563640
[TBL] [Abstract][Full Text] [Related]
2. The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
Javellana M; Hoppenot C; Lengyel E
Gynecol Oncol; 2019 Feb; 152(2):228-234. PubMed ID: 30471899
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of 10-year survivors of high-grade serous ovarian carcinoma.
Dao F; Schlappe BA; Tseng J; Lester J; Nick AM; Lutgendorf SK; McMeekin S; Coleman RL; Moore KN; Karlan BY; Sood AK; Levine DA
Gynecol Oncol; 2016 May; 141(2):260-263. PubMed ID: 26968641
[TBL] [Abstract][Full Text] [Related]
4. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium.
Guan J; Darb-Esfahani S; Richter R; Taube ET; Ruscito I; Mahner S; Woelber L; Prieske K; Concin N; Vergote I; Van Nieuwenhuysen E; Achimas-Cadariu P; Glajzer J; Woopen H; Stanske M; Kulbe H; Denkert C; Sehouli J; Braicu EI
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1063-1073. PubMed ID: 30810838
[TBL] [Abstract][Full Text] [Related]
6. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment.
Yalcin I; Meydanli MM; Turan AT; Taskin S; Sari ME; Gungor T; Akbayir O; Ayhan A
Int J Clin Oncol; 2018 Apr; 23(2):329-337. PubMed ID: 29143144
[TBL] [Abstract][Full Text] [Related]
7. Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival.
Darb-Esfahani S; Kolaschinski I; Trillsch F; Mahner S; Concin N; Vergote I; Van Nieuwenhuysen E; Achimas-Cadariu P; Glajzer J; Woopen H; Wienert S; Taube ET; Stanske M; Kulbe H; Denkert C; Sehouli J; Braicu EI
Histopathology; 2018 Dec; 73(6):1002-1012. PubMed ID: 30007074
[TBL] [Abstract][Full Text] [Related]
8. Who are the long-term survivors of high grade serous ovarian cancer?
Hoppenot C; Eckert MA; Tienda SM; Lengyel E
Gynecol Oncol; 2018 Jan; 148(1):204-212. PubMed ID: 29128106
[TBL] [Abstract][Full Text] [Related]
9. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
10. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Long-Term Survival among High-Grade Serous Ovarian Cancer Patients.
Clarke CL; Kushi LH; Chubak J; Pawloski PA; Bulkley JE; Epstein MM; Burnett-Hartman AN; Powell B; Pearce CL; Spencer Feigelson H
Cancer Epidemiol Biomarkers Prev; 2019 May; 28(5):996-999. PubMed ID: 30967418
[TBL] [Abstract][Full Text] [Related]
12. Comparison of survival outcomes in optimally and maximally cytoreduced stage IIIC ovarian high-grade serous carcinoma: Women with only peritoneal tumor burden versus women with both peritoneal and lymphogenous dissemination.
Selcuk I; Meydanli MM; Yalcin I; Gungorduk K; Akgol S; Çelik H; Ayhan A
J Obstet Gynaecol Res; 2019 Oct; 45(10):2074-2081. PubMed ID: 31373110
[TBL] [Abstract][Full Text] [Related]
13. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer.
Paik ES; Kim JH; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH
J Gynecol Oncol; 2018 Jan; 29(1):e13. PubMed ID: 29185271
[TBL] [Abstract][Full Text] [Related]
15. Impact of cytoreductive surgery on survival of patients with low-grade serous ovarian carcinoma: A multicentric study of Turkish Society of Gynecologic Oncology (TRSGO-OvCa-001).
Vatansever D; Taskiran C; Mutlu Meydanli M; Gungorduk K; Akbayir O; Yalcin I; Demirkiran F; Sozen H; Ozgul N; Celik H; Onan MA; Taskin S; Oge T; Simsek T; Abboud S; Yuksel IT; Ayhan A
J Surg Oncol; 2021 May; 123(8):1801-1810. PubMed ID: 33657253
[TBL] [Abstract][Full Text] [Related]
16. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
[TBL] [Abstract][Full Text] [Related]
17. Impact of lympho-vascular space invasion on tumor characteristics and survival outcome of women with low-grade serous ovarian carcinoma.
Matsuo K; Wong KK; Fotopoulou C; Blake EA; Robertson SE; Pejovic T; Frimer M; Pardeshi V; Hu W; Choi JS; Sun CC; Richmond AM; Marcus JZ; Hilliard MAM; Mostofizadeh S; Mhawech-Fauceglia P; Abdulfatah E; Post MD; Saglam O; Shahzad MMK; Karabakhtsian RG; Ali-Fehmi R; Gabra H; Roman LD; Sood AK; Gershenson DM
J Surg Oncol; 2018 Feb; 117(2):236-244. PubMed ID: 28787528
[TBL] [Abstract][Full Text] [Related]
18. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
19. Grading ovarian serous carcinoma using a two-tier system.
Malpica A; Deavers MT; Lu K; Bodurka DC; Atkinson EN; Gershenson DM; Silva EG
Am J Surg Pathol; 2004 Apr; 28(4):496-504. PubMed ID: 15087669
[TBL] [Abstract][Full Text] [Related]
20. Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability.
Torres D; Wang C; Kumar A; Bakkum-Gamez JN; Weaver AL; McGree ME; Konecny GE; Goode EL; Cliby WA
Gynecol Oncol; 2018 Aug; 150(2):227-232. PubMed ID: 29925470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
